TRT and hormone optimization: separating hype from clinical evidence

What's this video probably claiming?

A nurse practitioner posting under hashtags like #hormoneoptimization and #menshealthwareness is almost certainly covering some version of the testosterone optimization narrative that has taken over men's health content in the last two years. That typically means claims about symptoms of low testosterone being underdiagnosed, assertions that "normal" lab ranges are too broad to be clinically useful, and suggestions that optimizing testosterone levels above baseline can improve energy, body composition, libido, and cognitive function. There may also be framing around how men deserve better hormone care, which is a legitimate point that gets weaponized to justify treating men whose labs fall within established reference ranges. Expect a mix of genuinely useful patient education and some extrapolation from early-phase research dressed up as settled science.

What does the science actually show?

The evidence for TRT in men with confirmed hypogonadism, defined as total testosterone consistently below 300 ng/dL with corresponding symptoms, is actually pretty solid. The Testosterone Trials (Snyder et al., 2016, NEJM) enrolled 790 men aged 65 and older and found meaningful improvements in sexual function and some mood measures, with modest gains in bone density. A 2023 meta-analysis by Lincoff et al. in NEJM, covering over 5,200 men in the TRAVERSE trial, found no significant increase in major adverse cardiovascular events over a median 33 months, which addressed a major safety concern from the 2010 Basaria et al. study that spooked the field. Muscle and fat mass changes are real but modest without concurrent resistance training. What the evidence does not support is treating men with testosterone in the low-normal range (300-400 ng/dL) purely for optimization when symptoms are nonspecific.

Where does the social media noise diverge from clinical reality?

The optimization framing is where things get clinically sloppy. Influencer content, including content from well-meaning NPs, tends to conflate hypogonadism treatment with performance enhancement. The idea that getting your testosterone to 800-1000 ng/dL makes you measurably healthier than being at 550 ng/dL is not backed by dose-response data in the clinical literature. The Endocrine Society's 2018 clinical practice guidelines specifically discourage treating men without clear hypogonadism. There is also a consistent underdiscussion of real risks: erythrocytosis occurs in roughly 20-25% of TRT patients per the TRAVERSE data, requiring monitoring. Fertility suppression through HPG axis suppression is frequently glossed over in social content. Injection site protocols and the need for baseline PSA and hematocrit testing before initiation rarely make it into a 60-second TikTok.

What should you actually know?

If you are a man experiencing fatigue, low libido, brain fog, or mood changes, getting your testosterone checked is reasonable. But a single morning total testosterone plus a free testosterone and LH/FSH panel tells you far more than one number alone. Reference ranges exist for a reason: the Endocrine Society defines biochemical hypogonadism as two fasting morning total testosterone values below 300 ng/dL. Before attributing symptoms to low testosterone, clinicians should rule out thyroid dysfunction, sleep apnea (which independently suppresses testosterone), obesity, and depression. TRT is a long-term commitment. It typically suppresses endogenous production within weeks, making discontinuation complicated. Any conversation about starting TRT that doesn't include fertility implications, monitoring requirements, and realistic expectations about what the therapy will and won't fix should be treated as incomplete, regardless of how confident the presenter sounds.